|
|
Aspect Biosystems Named to Fast Company's 2023 List of the 'Next Big Things in Tech'
|
Vancouver, BC, December 1, 2023--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of disease, announced that it has been named to Fast Company's third annual Next Big Things in Tech list, honoring technological breakthroughs that promise to shape the future of industries — from healthcare and security to artificial intelligence and data.
|
|
|
|
|
|
|
Aspect Biosystems Appoints Three New Board Members
|
Vancouver, BC, October 5, 2022--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, announced the appointment of three new members to its Board of Directors: Dr. Nancy Krieger, Dr. Don Haut, and Dr. Devyn Smith.
|
|
|
|
|
Aspect Biosystems Appoints Five New Scientific Advisors
|
Vancouver, BC, June 13, 2022--Aspect Biosystems, a biotechnology company pioneering the development of bioengineered tissue therapeutics to transform how we treat disease, announced the appointment of five new advisors to the Company's Scientific Advisory Board (SAB). Appointments include Dr. James Shapiro, Dr. Anil Dhawan, Dr. Jane Lebkowski, Dr. Shinichiro Ogawa, and Dr. Omid Veiseh.
|
|
|
|
|
Aspect Biosystems Enters Collaboration With McMaster University
|
Vancouver, BC, September 3, 2019--Aspect Biosystems, a Canadian biotech company pioneering microfluidic 3D bioprinting of human tissues, is pleased to announce a collaboration with Dr. Jeremy Hirota - Canada Research Chair in Respiratory Mucosal Immunology - at the Firestone Institute for Respiratory Health located at McMaster University.
|
|
|
|
|